DOCSLIB.ORG

Neoplasms of the Posterior Fossa 1.4 Kelly K

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neoplasms of the Posterior Fossa 1.4 Kelly K Chapter Neoplasms of the Posterior Fossa 1.4 Kelly K. Koeller Contents The opinions and assertions contained herein are the private views of the author and are not to be construed Introduction . 69 as official or representing the views of the Departments Pediatric Neoplasms . 69 of the Navy or Defense. Medulloblastoma . 69 Incidence and Clinical Presentation . 69 Pathologic Findings . 70 Introduction Imaging Findings . 70 Pilocytic Astrocytoma . 71 Incidence and Clinical Presentation . 71 Neoplasms of the posterior fossa form a heterogeneous Pathologic Findings . 72 group of tumors that manifest either within the cerebel- Imaging Findings . 72 lum, the fourth ventricle, or the cisternal spaces. Using Ependymoma . 73 the predominant age group in which each occurs is a Incidence and Clinical Presentation . 73 convenient method to analyze this group. Pathologic Findings . 73 Within the pediatric population, medulloblastoma Imaging Findings . 73 and pilocytic astrocytoma arise within the cerebellum Choroid Plexus Papilloma and Carcinoma . 74 Incidence and Clinical Presentation . 74 while ependymoma and choroid plexus papilloma oc- Pathologic Findings . 74 cur within the ventricular system. In the adult popula- Imaging Findings . 74 tion, hemangioblastoma is the most common cerebellar Atypical Teratoid / Rhabdoid Tumor . 75 tumor, followed by dysplastic cerebellar gangliocytoma Adult Tumors . 76 (Lhermitte-Duclos disease) and cerebellar liponeuro- Hemangioblastoma . 76 cytoma while the fourth ventricle is the most common Incidence and Clinical Presentation . 76 location for the subependymoma. In the extra-axial Pathologic Findings . 76 cerebellopontine angle, the vestibular schwannoma is Imaging Findings . 77 the most common tumor, followed by meningioma. Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease) . 77 Incidence and Clinical Presentation . 77 Pathologic Findings . 78 Pediatric Neoplasms Imaging Findings . 78 Cerebellar Liponeurocytoma . 78 Medulloblastoma Subependymoma . 78 Incidence and Clinical Presentation . 78 Incidence and Clinical Presentation Pathologic Findings . 79 Imaging Findings . 79 Medulloblastoma is the most common pediatric central Cerebellopontine Angle Tumors . 79 nervous system malignancy and the most common Vestibular schwannoma . 79 (38%) primary tumor of the posterior fossa in children. Incidence and Clinical Presentation . 79 Pathologic Findings . 80 Following only astrocytoma, it is the second most com- Imaging Findings . 80 mon pediatric brain neoplasm overall (6–8%) with an Meningioma . 81 incidence of about 1 in 200,000 [1–7]. Males (60%) are Incidence and Clinical Presentation . 81 slightly more commonly affected [5]. Among children, Pathologic Findings . 81 the mean age is about 7 years with small peaks at 3 years Imaging Findings . 81 and 7 years [3]. Other cases may manifest between the Other Tumors . 81 ages of 20 and 40 years [8, 9]. Conclusion . 81 Nearly all cases occur in the cerebellum (94.4%) and References . 81 most (>75%) of these arise in the midline cerebellar 70 Kelly K. Koeller vermis [3, 10]. A more lateral location within the cere- moplastic subtype, characterized by nodular reticulin- bellar hemisphere is typical when these tumors mani- free “pale islands” that are surrounded by reticulin- fest in older children, adolescents, and adults, and is staining collagen fibers, the “medulloblastoma with likely related to the lateral migration of undifferentiated extensive nodularity and advanced neuronal differen- cells, the putative cell of origin, away from the midline tiation” subtype, occurring primarily in children less in older children and adolescents [3, 6, 11]. Brain stem than 3 years of age and associated with a “grape-like” infiltration is a common (33%) manifestation [12]. Less nodularity seen on imaging studies, and the large cell common locations include the fourth ventricle (3%), medulloblastoma subtype [10]. The loss of genetic other areas of the brain (2.1%), and spinal cord (0.6%) material from chromosomal arm 17p, site of a suppres- [3]. sor gene, is the most common (35–40%) of many chro- The clinical presentation is usually less than 3 months mosomal abnormalities associated with this disease in duration, reflecting the tumor’s aggressive biologic [24]. Medulloblastoma, a WHO grade IV tumor, is behavior [12, 13]. Headache (generalized or localized to regarded as a distinct entity from primitive neuro- the suboccipital region) and persistent vomiting (with- ectodermal tumor (PNET) in the WHO classification out or with nausea) are common symptoms [12,13].Sei- scheme [10]. zure activity is uncommon and may herald metastatic spread [13]. Truncal ataxia, secondary to destruction of the cerebellar vermis, is the most common objective Imaging Findings clinical sign. and is frequently accompanied by spastic- ity [12, 13]. Other common clinical signs include papil- The classic computed tomography (CT) appearance of a ledema (related to hydrocephalus), nystagmus, limb medulloblastoma is a hyperattenuated well-defined ver- ataxia, and dysdiadochokinesis, the last two findings re- mian cerebellar mass with surrounding vasogenic ede- flecting a more laterally located mass within the cere- ma, evidence of hydrocephalus, and fairly uniform con- bellar hemisphere [12,13].Abducens nerve palsy,result- trast enhancement on post-contrast images in a child ing from compression of the relatively exposed sixth less than 10 years of age [13, 25, 26] (Fig. 1). Most nerve nucleus along the anterior margin of the fourth (89–95%) of all medulloblastomas demonstrate at least ventricle, may indicate extraventricular tumor exten- some hyperattenuation compared to normal cerebellar sion [13]. attenuation on nonenhanced CT and have marginal vas- Most patients with medulloblastoma have 5-year ogenic edema [13, 25, 27] Heterogeneity, with cyst for- survival rates between 50% and 80% [13–19]. Patients mation (59%) and calcification (22%), are commonly with gross total resection of the tumor have improved survival rates compared to those with subtotal resection [12, 18, 20]. Recurrence of medulloblastoma is very common with most occurring within 2 years of initial treatment [21, 22]. Long-term recurrences may also oc- cur in children but are less common with the imple- mentation of chemotherapy in combination with radia- tion therapy [21–23]. Pathologic Findings The gross appearance of a medulloblastoma is variable. Some are firm and discrete masses while others may be soft and less well-defined [10]. Four major subtypes of the tumor are recognized in the World Health Organiza- tion (WHO) classification of central nervous system (CNS) neoplasms [10]. The most common subtype is the classic subtype, defined by dense, sheet-like growth of cells with hyperchromatic round-to-oval nuclei ac- companied by increased mitotic activity and conspicu- ous apoptosis [10]. Neuroblastic or Homer-Wright ro- settes, consisting of neoplastic cell nuclei disposed in a radial arrangement around fibrillary processes, are Fig. 1. Medulloblastoma, CT appearance. Axial nonenhanced CT common features while areas of necrosis are less com- image demonstrates heterogeneous hyperattenuation of a vermian mon [10]. Other less common subtypes include the des- cerebellar mass with surrounding vasogenic edema Chapter 1.4 Neoplasms of the Posterior Fossa 71 seen [27]. Atypical features include ill-defined margins, results in the first 2 post-operative weeks, either from absence of vasogenic edema or hydrocephalus, hypoat- the presence of methemoglobin or from leptomeningeal tenuation, hemorrhage, absence of enhancement on irritation caused by subarachnoid blood [34] Corrobo- post-contrast images, and the appearance of “primary” ration with clinical and cytopathologic CSF findings is leptomeningeal dissemination [13, 25, 27–29]. The pres- crucial to substantiate the diagnosis of CSF dissemina- ence of falcine calcification in children with medullo- tion [35]. In contrast to ependymoma and choroid plex- blastoma may be a marker for nevoid basal cell carcino- us tumors, foraminal extension by a medulloblastoma ma [30]. from the fourth ventricle to involve the cerebellopon- On magnetic resonance (MR) imaging, an even tine angle (CPA), cisterna magna, and other cisternal greater degree of heterogeneity among these lesions is compartments is not common [27, 36]. noted on MR imaging than on CT [31]. Iso- to hypoin- Recurrence of medulloblastoma most commonly tensity compared to white matter on T1-weighted imag- manifests as leptomeningeal enhancement or focal pa- es and variable signal intensity compared to white mat- renchymal nodular enhancement within the brain [22]. ter on T2-weighted images is typical [31]. Virtually all Extraneural metastasis is uncommon (7.1%) with the (97%) show at least some enhancement on post-con- skeletal system as the most common (77%) site of in- trast imaging studies [27] (Fig. 2). MR spectroscopy volvement [37]. typically shows a characteristic,albeit not specific,spec- Medulloblastomas occurring in the adult population trographic signature for a neuroectodermal tumor with tend to manifest as hyperattenuated poorly defined elevated choline,reduced N-acetyl aspartate (NAA),and masses located in the cerebellar hemisphere. Cyst-like reduced creatine peaks, and occasionally elevated lipid regions, from either cystic degeneration or necrosis, are and lactic acid peaks [32]. Striking grape-like nodular- more commonly noted (82%) than in those that occur ity characterizes the CT and MR imaging appearance
Load more

Recommended publications
  • Neurofibromatosis Type 2 (NF2)
    International Journal of Molecular Sciences Review Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis Suha Bachir 1,† , Sanjit Shah 2,† , Scott Shapiro 3,†, Abigail Koehler 4, Abdelkader Mahammedi 5 , Ravi N. Samy 3, Mario Zuccarello 2, Elizabeth Schorry 1 and Soma Sengupta 4,* 1 Department of Genetics, Cincinnati Children’s Hospital, Cincinnati, OH 45229, USA; [email protected] (S.B.); [email protected] (E.S.) 2 Department of Neurosurgery, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (M.Z.) 3 Department of Otolaryngology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] (S.S.); [email protected] (R.N.S.) 4 Department of Neurology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] 5 Department of Radiology, University of Cincinnati, Cincinnati, OH 45267, USA; [email protected] * Correspondence: [email protected] † These authors contributed equally. Abstract: Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with loss of function in a tumor-suppressor protein that has a number of synonymous names, including: Merlin, Neurofibromin 2, and schwannomin. Merlin is a 70 kDa protein that has 10 different isoforms. The Hippo Tumor Suppressor pathway is regulated upstream by Merlin. This pathway is critical in regulating cell proliferation and apoptosis, characteristics that are important for tumor progression.
    [Show full text]
  • Information About Mosaic Neurofibromatosis Type 2 (NF2)
    Information about mosaic Neurofibromatosis type 2 (NF2) NF2 occurs because of a mutation (change) in the NF2 gene. When this change is present at the time of conception the changed gene will be present in all the cells of the baby. When this mutation occurs later in the development of the forming embryo, the baby will go on to have a mix of cells: some with the “normal” genetic information and some with the changed information. This mix of cells is called mosaicism. Approximately half the people who have a diagnosis of NF2 have inherited the misprinted NF2 gene change from their mother or father who will also have NF2. They will have that misprinted gene in all the cells of their body. When they have their children, there will be a 1 in 2 chance of passing on NF2 to each child they have. However about half of people with NF2 are the first person in the family to be affected. They have no family history and have not inherited the condition from a parent. When doctors studied this group of patients more closely they noticed certain characteristics. Significantly they observed that fewer children had inherited NF2 than expected some people in this group had relatively mild NF2 NF2 tumours in some patients tended to grow on one side of their body rather than both sides that when a blood sample was tested to identify the NF2 gene, the gene change could not be found in 30-40% of people This lead researchers to conclude that this group of people were most likely to be mosaic for NF2 i.e.
    [Show full text]
  • Simultaneous Neurofibroma and Schwannoma of the Sciatic Nerve
    Simultaneous Neurofibroma and Schwannoma of the Sciatic Nerve 1 4 1 1 2 3 1 S. A. Sintzoff, Jr.,I.5 W . 0. Bank, · P. A. Gevenois, C. Matos, J. Noterman, J. Flament-Durand, and J. Struyven Summary: The authors report a case of simultaneously occur­ MR imaging was performed on a 0.5-T system (Gyro­ ring neurofibroma and schwannoma of the sciatic nerve and scan T5, Philips Medical Systems, Eindhoven, The Neth­ discuss the complementary aspects of MR and OS. The Schwan­ erlands) using a wrap-around knee surface coil in order to norna was well-defined and showed distal enhancement on better define the relationships between the tumors and the sonographic evaluation, whereas the neurofibroma was ill-de­ nerve. Each tumor was isointense to the normal nerve on fined; both tumors were hypoechoic. Tl- and T2-weighted MR T1-weighted images and hyperintense to it on proton Images revealed similar signal characteristics of the two tumors, density and T2-weighted images (Fig. 2A-2C). After intra­ but Intense enhancement following administration of gadolin­ venous gadolinium-DTPA injection, the distal mass showed ium-DTPA distinguished the schwannoma from the neurofi­ intense enhancement, conserving a thin hypointense border broma. (Fig. 2D). Physical and neurologic examination, MR of the central nervous system and skeletal radiographs failed to Index terms: Nerves, sciatic; Neuroma; Schwannoma demonstrate any additional lesions, permitting the reason­ able exclusion of neurofibromatosis types 1 and 2. Schwannomas and neurofibromas are com­ Surgical exposure demonstrated the two tumors on the external popliteal nerve (Fig. 3). The distal tumor could be (1, mon peripheral nerve neoplasms 2).
    [Show full text]
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Ganglioneuroma of the Sacrum
    https://doi.org/10.14245/kjs.2017.14.3.106 KJS Print ISSN 1738-2262 On-line ISSN 2093-6729 CASE REPORT Korean J Spine 14(3):106-108, 2017 www.e-kjs.org Ganglioneuroma of the Sacrum Donguk Lee1, Presacral ganglioneuromas are extremely rare benign tumors and fewer than 20 cases have been reported in the literature. Ganglioneuromas are difficult to be differentiated preoperatively Woo Jin Choe1, from tumors such as schwannomas, meningiomas, and neurofibromas with imaging modalities. 2 So Dug Lim The retroperitoneal approach for resection of presacral ganglioneuroma was performed for gross total resection of the tumor. Recurrence and malignant transformation of these tumors is rare. 1 Departments of Neurosurgery and Adjuvant chemotherapy or radiation therapy is not indicated because of their benign nature. 2Pathology, Konkuk University Medical Center, Konkuk University We report a case of a 47-year-old woman with a presacral ganglioneuroma. School of Medicine, Seoul, Korea Key Words: Ganglioneuroma, Presacral, Anterior retroperitoneal approach Corresponding Author: Woo Jin Choe Department of Neurosurgery, Konkuk University Medical Center, displacing the left sacral nerve roots, without 120-1 Neungdong-ro, Gwangjin-gu, INTRODUCTION Seoul 05030, Korea any evidence of bony invasion (Fig. 2). We performed surgery via anterior retrope- Tel: +82-2-2030-7625 Ganglioneuroma is an uncommon benign tu- ritoneal approach and meticulous adhesiolysis Fax: +82-2-2030-7359 mor of neural crest origin which is mainly loca- was necessary because of massive abdominal E-mail: [email protected] lized in the posterior mediastinum, retroperito- adhesion due to the previous gynecologic sur- 1,6) Received: August 16, 2017 neum, and adrenal gland .
    [Show full text]
  • Downloaded 09/30/21 01:49 PM UTC NF2 Patients There Were Often Multiple Meningiomas
    Neurosurg Focus 4 (3):Article 1, 1998 Neurofibromatosis type 2 and central neurofibromatosis Leonard I. Malis, M.D. The Mount Sinai School of Medicine, New York City, New York Neurofibromatosis type 2 (NF2) is a rare disease, affecting only approximately 1000 patients in the entire United States. The diagnosis requires the presence of bilateral acoustic neuromas, but many other tumors of the nervous system are also present. It is a very different disease from von Recklinghausen's neurofibromatosis, NF1. The remarkable genetic research in recent years has defined the origin of NF2 to be the lack of a specific suppressor protein, known as Merlin. While we await a method to replace this protein, the neurosurgical care of these patients is a formidable problem. The author reviews his personal series of 41 patients with NF2 treated during the past 30 years and presents 10 cases in detail to demonstrate their considerable range of differences and the treatment problems they have posed. Key Words * neurofibromatosis type 2 * bilateral acoustic neurofibromatosis * central neurofibromatosis * bilateral acoustic neuromas * bilateral vestibular schwannomas * Merlin * schwannomin This review is based on my personal series of 41 surgically treated patients with neurofibromatosis type 2 (NF2). The patients were cared for in the microsurgical era between 1970 and 1995 and received minimum follow-up care of 3 years (median 12 years). All of these people were referred because of bilateral acoustic neuromas. This was a quite young group, with the average age only 20 years, much younger than my patients with solitary acoustic neuromas. The youngest patient was 8 years old and the oldest 40 years old when first referred.
    [Show full text]
  • Choroid Plexus Tumors: a Review
    UC San Diego UC San Diego Previously Published Works Title Perinatal (fetal and neonatal) choroid plexus tumors: a review. Permalink https://escholarship.org/uc/item/0sm7q5q7 Journal Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 35(6) ISSN 0256-7040 Authors Crawford, John R Isaacs, Hart Publication Date 2019-06-01 DOI 10.1007/s00381-019-04135-x Peer reviewed eScholarship.org Powered by the California Digital Library University of California Child's Nervous System (2019) 35:937–944 https://doi.org/10.1007/s00381-019-04135-x REVIEW ARTICLE Perinatal (fetal and neonatal) choroid plexus tumors: a review John R. Crawford1,2,3 & Hart Isaacs Jr3,4 Received: 13 September 2018 /Accepted: 20 March 2019 /Published online: 5 April 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Introduction The object of this review is to describe the choroid plexus tumors (CPTs) occurring in the fetus and neonate with regard to clinical presentation, location, pathology, treatment, and outcome. Materials and methods Case histories and clinical outcomes were reviewed from 93 cases of fetal and neonatal tumors obtained from the literature and our own institutional experience from 1980 to 2016. Results Choroid plexus papilloma (CPP) is the most common tumor followed by choroid plexus carcinoma (CPC) and atypical choroid plexus papilloma (ACPP). Hydrocephalus and macrocephaly are the presenting features for all three tumors. The lateral ventricles are the main site of tumor origin followed by the third and fourth ventricles, respectively. CPTs of the fetus are detected most often near the end of the third trimester of pregnancy by fetal ultrasound.
    [Show full text]
  • Diagnostic Value of Preoperative Inflammatory Markers in Patients with Glioma: a Multicenter Cohort Study
    CLINICAL ARTICLE J Neurosurg 129:583–592, 2018 Diagnostic value of preoperative inflammatory markers in patients with glioma: a multicenter cohort study *Shi-hao Zheng, MD,1 Jin-lan Huang, PhD,2,4 Ming Chen, MD,3 Bing-long Wang, BS,2 Qi-shui Ou, PhD,2 and Sheng-yue Huang, BS1 1Department of Neurosurgery, Fujian Provincial Hospital; 2Department of Clinical Laboratory, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian; 3Department of Neurosurgery, Xin Hua Hospital, Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai; and 4Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China OBJECTIVE Glioma is the most common form of brain tumor and has high lethality. The authors of this study aimed to elucidate the efficiency of preoperative inflammatory markers, including neutrophil/lymphocyte ratio (NLR), derived NLR (dNLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), and prognostic nutritional index (PNI), and their paired combinations as tools for the preoperative diagnosis of glioma, with particular interest in its most aggressive form, glioblastoma (GBM). METHODS The medical records of patients newly diagnosed with glioma, acoustic neuroma, meningioma, or nonle- sional epilepsy at 3 hospitals between January 2011 and February 2016 were collected and retrospectively analyzed. The values of NLR, dNLR, PLR, LMR, and PNI were compared among patients suffering from glioma, acoustic neuroma, meningioma, and nonlesional epilepsy and healthy controls by using nonparametric tests. Correlations between NLR, dNLR, PLR, LMR, PNI, and tumor grade were analyzed. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic significance of NLR, dNLR, PLR, LMR, PNI, and their paired combinations for glioma, particularly GBM.
    [Show full text]
  • Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma Or Ependymoma (Sjyc07)
    SJCRH SJYC07 CTG# - NCT00602667 Initial version, dated: 7/25/2007, Resubmitted to CPSRMC 9/24/2007 and 10/6/2007 (IRB Approved: 11/09/2007) Activation Date: 11/27/2007 Amendment 1.0 dated January 23, 2008, submitted to CPSRMC: January 23, 2008, IRB Approval: March 10, 2008 Amendment 2.0 dated April 16, 2008, submitted to CPSRMC: April 16, 2008, (IRB Approval: May 13, 2008) Revision 2.1 dated April 29, 2009 (IRB Approved: April 30, 2009 ) Amendment 3.0 dated June 22, 2009, submitted to CPSRMC: June 22, 2009 (IRB Approved: July 14, 2009) Activated: August 11, 2009 Amendment 4.0 dated March 01, 2010 (IRB Approved: April 20, 2010) Activated: May 3, 2010 Amendment 5.0 dated July 19, 2010 (IRB Approved: Sept 17, 2010) Activated: September 24, 2010 Amendment 6.0 dated August 27, 2012 (IRB approved: September 24, 2012) Activated: October 18, 2012 Amendment 7.0 dated February 22, 2013 (IRB approved: March 13, 2013) Activated: April 4, 2013 Amendment 8.0 dated March 20, 2014. Resubmitted to IRB May 20, 2014 (IRB approved: May 22, 2014) Activated: May 30, 2014 Amendment 9.0 dated August 26, 2014. (IRB approved: October 14, 2014) Activated: November 4, 2014 Un-numbered revision dated March 22, 2018. (IRB approved: March 27, 2018) Un-numbered revision dated October 22, 2018 (IRB approved: 10-24-2018) RISK-ADAPTED THERAPY FOR YOUNG CHILDREN WITH EMBRYONAL BRAIN TUMORS, HIGH-GRADE GLIOMA, CHOROID PLEXUS CARCINOMA OR EPENDYMOMA (SJYC07) Principal Investigator Amar Gajjar, M.D. Division of Neuro-Oncology Department of Oncology Section Coordinators David Ellison, M.D., Ph.D.
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • A Case of Cerebral Astroblastoma with Rhabdoid Features : a Cytological, Histological, and Immunohistochemical Study
    Title A case of cerebral astroblastoma with rhabdoid features : a cytological, histological, and immunohistochemical study Yuzawa, Sayaka; Nishihara, Hiroshi; Tanino, Mishie; Kimura, Taichi; Moriya, Jun; Kamoshima, Yuuta; Nagashima, Author(s) Kazuo; Tanaka, Shinya Brain tumor pathology, 33(1), 63-70 Citation https://doi.org/10.1007/s10014-015-0241-5 Issue Date 2016-01 Doc URL http://hdl.handle.net/2115/63975 Rights The final publication is available at link.springer.com Type article (author version) File Information Astroblastoma_yuzawa_HUSCAP.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Case report A case of cerebral astroblastoma with rhabdoid features: a cytological, histological, and immunohistochemical study Sayaka Yuzawa1, Hiroshi Nishihara2, 3, Mishie Tanino1, Taichi Kimura2, 3, Jun Moriya1, Yuuta Kamoshima4, 5, Kazuo Nagashima6, and Shinya Tanaka1, 2. 1Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan. 2Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 3Translational Research Laboratory, Hokkaido University Hospital, Clinical Research and Medical Innovation Center, Sapporo, Japan. 4Sapporo Azabu Neurosurgical Hospital, Sapporo, Japan. 5Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 6Higashi Tokushukai Hospital, Sapporo, Japan. Correspondence: Shinya Tanaka Department of Cancer Pathology, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan. Tel: +81-11-706-5053 Fax: +81-11-706-5902 E-mail: [email protected] 1 Abstract Astroblastoma is a rare neuroepithelial neoplasm of unknown origin, usually occurring in children and young adults. Here we report a case of astroblastoma with uncommon features in an 18-year-old female.
    [Show full text]
  • Multiple Inherited Schwannomas, Meningiomas, and Ependymomas Syndrome in an Adult Patient
    Published online: 2021-05-23 Practitioner Section Multiple Inherited Schwannomas, Meningiomas, and Ependymomas Syndrome in an Adult Patient Abstract Vijay Parshuram Neurofibromatosis type 2 (NF2) is also known as multiple inherited schwannomas, meningiomas, Raturi, and ependymomas (MISME) syndrome. Mutation in NF2 gene is the cause for MISME syndrome. Rahul Singh We are reporting here a case of MISME syndrome with triple tumor in a 30‑year‑old male patient Department of Radiotherapy, who presented with the chief complaints of spastic paraparesis, bowel and bladder incontinence, and King George Medical decreased vision in the right eye. University, Lucknow, Uttar Pradesh, India Keywords: Ependymoma, meningioma, multiple inherited schwannomas, and neurofibromatosis Introduction system shows tone to be normal in the upper limb and power grade 5/5 in the bilateral Neurofibromatosis type 2 (NF2) incidence is upper limb. Tone reduced in bilateral 1 in 33,000 and prevalence is 1 in 60,000.[1,2] lower limbs. Deep tendon reflex was It has no predilection for sex, race, and absent in bilateral lower limbs. Pure‑tone ethnicity, and it is most commonly seen in audiometry showed bilateral sensory neural the second and third decades of life that too deafness, which was more on the right side. most commonly between 16 and 24 years Ophthalmic evaluation was done and was of age.[3] Approximately 50% of cases are suggestive of macular corneal opacity of familial and remaining 50% are sporadic in the left eye and central serous retinopathy nature.[4] NF2 is caused by the mutation in with nystagmus in the right eye. MRI merlin gene, which is located on the long brain with contrast showed a well‑defined arm of chromosome 22 (22q12.2).[5] The enhancing extra‑axial space‑occupying hallmark for the diagnosis of NF2 is bilateral lesion (SOL) at left cerebellopontine (CP) vestibular schwannomas on magnetic angle largest measuring 1.4 cm × 1.2 cm.
    [Show full text]